Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549
---------------	------------

Check this box if no longer subject	STATEMENT OF CHANGES IN BENEFICIAL	<b>OWNERSHIP</b>
to Section 16. Form 4 or Form 5		
obligations may continue. See		

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Bergstrom Donald A					2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [ RLAY ]									(Check	all app	o of Reportir licable) tor er (give title	ng Per	rson(s) to I 10% O Other (	wner
(Last) (First) (Middle) C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 04/16/2021									X	belov		emar	below)	
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check App Line)  X Form filed by One Reporting Person  Form filed by More than One Report Person									on				
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	uired	l, Dis	posed of	, or E	Benefic	cially	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				Execution (Year) if any		ition Date,				s Acquired (A) If (D) (Instr. 3, 4		4 and 5) See Be Ow		. Amount of Securities Seneficially Dwned Following Reported		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) o (D)	Price	Trans		action(s) 3 and 4)			()	
Common Stock 04/16/20				<u>'</u> 021				S <sup>(1)</sup>		56,324	D	\$32.	2.36 <sup>(2)</sup> 7		77,241		D		
		Tal	ble II						,		osed of, convertib			•	Owne	d			
1. Title of Derivative Security (Instr. 3)	rative Conversion Date Execution Date, if any		Code ( 8)	Transaction of Der Sec Acc (A) Dis of (		osed ) r. 3, 4	Expiration [		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)  Amount or Number of Title Share		Der Sec (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: / Direct (D or Indire (I) (Instr.	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

- $1. \ The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.$
- 2. This transaction was executed in multiple trades at prices ranging from \$31.59 to \$33.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

## Remarks:

Executive Vice President, Head of Research and Development

/s/ Brian Adams, as Attorney-

04/20/2021

in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.